Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02553941

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This phase Ib trial studies the side effects and best dose of ibrutinib when given together with azacitidine in treating patients with myelodysplastic syndrome that is likely to occur or spread (higher risk) and who were previously treated or untreated and unfit for or refused intense therapy. Ibrutinib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Status: 
Not yet recruiting
Study Date: 
Tue, 09/01/2015 to Tue, 11/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Azacitidine Given intravenous or subcutaneous Other Name: Vidaza Drug: Ibrutinib Given by mouth once daily Other Name: BTK Inhibitor